Although
acromegaly has been reported in patients with
Neurofibromatosis type 1 (NF1), these cases have not been associated with
growth hormone (GH)-producing
somatotroph adenoma, but with optic pathway
glioma. A 68 year-old Japanese woman, who had been clinically diagnosed with NF1, was referred to our hospital due to a thyroid
tumor and
hypercalcemia.
Acromegaly was suspected due to her facial features, and subsequent examinations revealed the presence of GH excess with a
pituitary tumor, leading to the diagnosis of
acromegaly. Histological and immunohistochemical analysis demonstrated an eosinophilic
pituitary adenoma with diffuse positivity for GH, indicating typical
somatotroph adenoma. In addition, her thyroid
tumor was diagnosed histologically as
follicular thyroid carcinoma (
FTC) with
primary hyperparathyroidism (PHPT). To investigate the pathogenesis of this untypical multiple endocrine
tumor case of NF1, genetic analysis was performed using peripheral leukocytes and tissue of resected
tumors. A heterozygous novel germline
nonsense mutation (p.Arg1534*) in exon 35 of the NF1 gene was detected from peripheral leukocytes, which results in a truncated
protein lacking the critical domain for
GTPase activity, strongly suggesting its causal role in NF1. The loss of heterozygosity (LOH) in exon 35 of the NF1 gene was not detected in the
somatotroph adenoma,
parathyroid adenoma, and
FTC. Although any mutations of the following genes; MEN1, CDKN1B, and PAX8-PPARĪ³ were not detected, a heterozygous GNAS R201C mutation was detected in the
somatotroph adenoma. To our knowledge, this is the first rare MEN1-like case of genetically diagnosed NF1 complicated with
acromegaly caused by a
somatotroph adenoma.